Rocket Pharmaceuticals: Strong Buy Rating on RP-A501’s Pivotal Study Progress and High Market Potential

3 weeks ago

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price …